Donna Costello
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Initiates Coverage on CTS with $67 Price Target. Lake Street initiated coverage on CTS Corporation this week, assigning a Buy rating and $67 price target. The analyst pointed to CTS's expanded current sensing distribution capabilities as a key driver, with separate analysis suggesting the stock could be trading approximately 14% below its assessed value based on this push. Q2 comparisons showed CTS performing in line with peers in the electronic components and manufacturing sector. The stock is currently trading near its 52-week range at the $60 support level, having touched its 200-day moving average recently.
Transaction History
| ROG | ▲ Buy | Grant | 1,427 | $0 | 5/6/2026 | View on chart |
| CTS | ▲ Buy | Grant | 3,500 | $0 | 11/6/2025 | View on chart |
| ROG | ▲ Buy | Grant | 2,760 | $0 | 5/5/2025 | View on chart |
| CTS | ▲ Buy | Grant | 2,400 | $0 | 11/7/2024 | View on chart |
| ROG | ▲ Buy | Grant | 1,500 | $0 | 5/2/2024 | View on chart |
| ROG | ▲ Buy | Grant | 450 | $0 | 1/22/2024 | View on chart |
| CTS | ▲ Buy | Grant | 3,600 | $0 | 11/2/2023 | View on chart |
| CTS | ▲ Buy | Grant | 3,100 | $0 | 11/10/2022 | View on chart |
| CTS | ▲ Buy | Grant | 3,600 | $132K | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.